BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE (BNTX) 42nd Annual J.P. Morgan Healthcare Conference (Transcript)

COVID-19 vaccine maker BioNTech on Tuesday forecast total company revenues of about 3 billion euros ($3.28 billion)for 2024, as it works to scale up its oncology business with product launches in the coming years.

BioNTech expects 2024 revenues of about $3.3 bln

Mainz, Germany, January 9, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) provided its full year 2024 revenue guidance as part of its outlined 2024 strategic priorities today at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California.

BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference

BioNTech is diversifying its portfolio beyond its COVID-19 vaccine, focusing on antibody-drug conjugates (ADCs) and novel vaccines. The company has acquired MediLink Therapeutics' ADC technology and is targeting HER3 protein-related tumors in cancer treatment. Despite a decline in revenue and profit, BioNTech remains financially robust with strong cash reserves and a solid current ratio.

BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics

BioNTech and Pfizer's COVID-19 vaccine, COMIRNATY, generated $36.8 billion in sales in 2021, making it the highest-selling pharmaceutical product in a single year. BioNTech's stock has faced challenges due to competition and declining COVID-19 demand, leading to the stock dropping 29% this year. However, it has a promising pipeline of therapies in ongoing trials and the potential for recurring revenue from annual COVID-19 booster shots.

BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline

MAINZ, Germany and SHANGHAI, China, December 21, 2023 –  BioNTech SE  (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co. Ltd. (“DualityBio”) today announced that the U.S. Food and Drug Administration (“FDA”) granted Breakthrough Therapy designation for BNT323/DB-1303 for the treatment of advanced endometrial cancer in patients who progressed on or after treatment with immune checkpoint inhibitors. BNT323/DB-1303 is a next-generation antibody-drug conjugate (“ADC”) candidate targeting the Human Epidermal Growth Factor Receptor 2 (“HER2”), a cell surface protein which is expressed in a range of tumor types. The designation is based on encouraging topline data from a Phase 1/2 study ( NCT05150691 ) with BNT323/DB-1303 in patients with HER2-expressing advanced endometrial cancer.

BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer

COVID-19 vaccine maker BioNTech aims to start production at its mRNA vaccine factory site in Rwanda in 2025, company officials said on Monday, the first foreign company mRNA vaccine manufacturing site on the continent.

BioNTech aims to start mRNA vaccine output in Rwanda in 2025

KIGALI, Rwanda, December 18, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) has reached the next milestone in the establishment of mRNA vaccine manufacturing capacities in Africa with the inauguration of the Company's site in Kigali, Rwanda. The inauguration takes place on the occasion of the set-up of the first manufacturing unit called BioNTainer. This effort is one of BioNTech's multiple initiatives aimed at helping to build a sustainable and resilient African vaccine ecosystem and supporting equitable access to novel medicines globally: these cover research and development, clinical trials, manufacturing and local training of specialized personnel.

BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda

JD.com

Moderna

BioNTech's pipeline should take center stage going forward. JD.com is dirt cheap after a big sell-off.

3 Stocks Down 30% or More This Year That Wall Street Expects to Skyrocket in 2024

Alibaba

Chevron

Barrick Gold

Alphabet

Hertz

Madison Square Garden Sports

PepsiCo

AMERCO

Barron's annual list of unloved stocks ranges from tech giant Alibaba to miner Barrick to auto rental stalwart Hertz Global.

Barron's Favorite 10 Stocks for 2024

MAINZ, Germany , December 12, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will inaugurate its first African site in Kigali, Rwanda, on Monday, December 18th, 2023. The inauguration takes place on the occasion of the set-up of the containers for the first manufacturing unit called BioNTainer.

BioNTech to Inaugurate First African Site on December 18, 2023

Moderna and BioNTech are pioneering companies in mRNA technology, known for their fast development of highly effective COVID-19 vaccines. Both companies have the potential to transform the treatment landscape for various diseases, including cancer and infectious diseases. Both companies hold late-stage assets that pave the road for near-term growth.

BioNTech Vs. Moderna: Navigating The mRNA Landscape

COVID-19 vaccine maker BioNTech said on Tuesday the European Patent Office has declared as invalid an mRNA patent that has been invoked by Moderna in litigation about alleged an patent violation by BioNTech and its partner Pfizer.

BioNTech says European Patent Office has declared Moderna patent invalid

Cencora Inc

McKesson

Biotechnology is a booming industry recently focused on synthetic biology, biomanufacturing and gene editing. Biotech is seen as the key to the future, as it has the potential to cure diseases and save many lives.

3 Biotech Stocks You'll Regret Not Buying Soon: November 2023

AstraZeneca

Boston Scientific

Senti Biosciences Inc

Eccogene out-licenses global rights for its GLP-1 agonist to AstraZeneca in a $2 billion deal. Biotheus sells ex-China rights for a bispecific antibody candidate to BioNTech for $55 million upfront. WuXi XDC conducts a $500 million Hong Kong IPO to expand its manufacturing capacity for ADCs and bioconjugates.

Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal

Corcept Therapeutics

Genmab - ADR

Halozyme Therapeutics

Incyte

Kiniksa Pharmaceuticals Ltd

Regeneron Pharmaceuticals

Amid some rising questions for the economy, value-seeking investors may want to consider underappreciated biotech stocks. As a sector that, while not immune to broader pressures, generally manages to march to its own beat, the underlying innovation may offer an alternative upside pathway.

7 Underappreciated Biotech Stocks to Pick Up on the Cheap

BioNTech SE (NASDAQ:BNTX ) Q3 2023 Earnings Call Transcript November 8, 2023 8:00 AM ET Company Participants Victoria Meissner - VP, Strategy & IR Ugur Sahin - Co-Founder & CFO Ozlem Tureci - Chief Medical Officer & Co-Founder Jens Holstein - CFO Ryan Richardson - Chief Strategy Officer Conference Call Participants Daina Graybosch - Leerink Partners Tazeen Ahmad - Bank of America Chris Shibutani - Goldman Sachs Yaron Werber - TD Cowen Jessica Fye - JPMorgan Bill Maughan - Canaccord Genuity Simon Baker - Redburn Atlantic Ellie Merle - UBS Operator Welcome to the BioNTech Third Quarter 2023 Update Call. I would like to hand the call over to Dr. Victoria Meissner, Vice President of Strategy and Investor Relations.

BioNTech SE (BNTX) Q3 2023 Earnings Call Transcript

BioNTech (BNTX) slashed its outlook for sales of its COVID-19 vaccine, but its American depositary receipts (ADRs) jumped over 4% in early trading Monday after the biotech firm posted a surprise profit as it lowered expenses.

BioNTech Posts a Profit, While Cutting Its Full-Year COVID Vaccine Sales Outlook

Bumble

Freshpet

OrganiGram Holdings Inc.

Tesla

Dish Network (NASDAQ:DISH), down 10% to $4.94, reported a drop in third-quarter revenue amid declining pay-TV subscribers,  triggering a loss for its fiscal third quarter. The US owner of the direct-broadcast satellite provider Dish said in a statement that pay-TV subscribers decreased by roughly 64,000 in Q3, compared to a net increase of approximately 30,000 in the year-ago quarter.

Tesla, Organigram, BioNTech, Dish, Bumble, FreshPet, Berkshire Hathaway – Stocks on the move

BioNTech unexpectedly reported a third-quarter profit and better-than-expected sales on Monday, pushing BNTX stock higher.

BioNTech Stock Jumps On Surprise Profit, Sales Beat

Shares have dropped 36% this year as demand for its coronavirus inoculations has fallen.

BioNTech Earnings Beat. Pfizer's Vaccine Partner Battles Covid Downturn.

BioNTech SE has lowered its forecast for this year's Covid-19 vaccine sales by 20%, becoming the latest drugmaker to adjust its expectations in the post-pandemic era. The German company said it now expects 2023 vaccine sales of around €4 billion, down from previous guidance of €5 billion.

BioNTech slashes revenue outlook amid lower Covid vaccine sales

BioNTech SE's stock BNTX, +3.56% rallied premarket after the company posted a surprise profit for the third quarter and revenue that beat estimates, even as it was hit by lower COVID-19 vaccine revenue. The German company said it had net profit of 160.6 million euros ($172.7 million), or 67 cents a share, down from EUR1.785 billion, or EUR6.98 a share, in the year-earlier period.

BioNTech's stock rallies after it posts surprise Q3 profit and revenue that tops estimates

BioNTech has cut its 2023 revenue target by about 1 billion euros ($1.1 billion) on lower demand for the COVID-19 vaccine made with Pfizer but said the impact from write-downs at its U.S. partner was less then initially thought.

BioNTech cuts 2023 revenue target on reduced prospects for vaccine

Positive clinical data updates across multiple drug classes including antibody-drug conjugate (ADC) candidates BNT323/DB-1303, BNT325/DB-1305, CAR-T candidate BNT211, T cell therapy candidate BNT221 and mRNA cancer vaccine candidate BNT116 Progress across the oncology pipeline with multiple late-stage trials initiated since third quarter start New and expanded strategic collaborations reflect BioNTech's commitment to delivering transformational therapies for oncology and infectious diseases Successful launches of Omicron XBB.1.5-adapted monovalent COVID-19 vaccine in markets worldwide Updated 2023 COVID-19 vaccine revenue guidance of around €4 billion Guidance reduction of planned 2023 R&D expenses to €1.8-2.0 billion and SG&A expenses to €600-650 million First nine months of 20231 revenues of €2.3 billion2, net profit of €472 million and diluted earnings per share of €1.94 ($2.113) Conference call and webcast scheduled for November 6, 2023, at 8:00 am ET (2:00 pm CET) MAINZ, Germany, November 6, 2023 (GLOBE NEWSWIRE) --  BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today reported financial results for the three and nine months ended September 30, 2023, and provided an update on its corporate progress. “Over the last quarter, we complemented our investigational pipeline with ADC candidates, initiated later-stage clinical trials and presented significant data across modalities including cancer vaccines, cell therapies, ADCs and immune checkpoint modulators.

News for BioNTech SE Stock (BNTX)